MGTX Stock Analysis: Buy, Sell, or Hold?
MGTX - MeiraGTx Holdings plc Ordinary Shares
$11.88
0.09 (0.76%)
▲
5d:
-3.41%
30d:
-14.66%
90d:
+26.25%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When MGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MGTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: MGTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: MGTX is currently trading at $11.88, which is considered slightly low relative to its 30-day fair value range of $11.82 to $13.50.
Technical Outlook: Technically, MGTX is in a strong uptrend. Immediate support is located at $11.28, while resistance sits at $12.76.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.29 (+146.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MGTX is in a strong uptrend. Immediate support is located at $11.28, while resistance sits at $12.76.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.29 (+146.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.82 -
$13.50
Company Quality Score
58/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 23th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 146.5% below Wall St target ($29.29)
Trading Range Analysis
30-Day Trading Range
$11.82 -
$13.50
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.59
(13.4%)
Support & Resistance Levels
Support Level
$11.28
Resistance Level
$12.76
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.71
Wall Street Target
$29.29
(+146.5%)
Revenue Growth (YoY)
-84.8%
Profit Margin
-151.1%
Share & Embed Analysis
Last updated: August 04, 2026 6:08 AM ET
Data refreshes hourly during market hours. Next update: 7:08 AM
Data refreshes hourly during market hours. Next update: 7:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Giroux
SELL
56000 shares
2026-04-21
Stuart Naylor
SELL
27661 shares
2026-04-07
Alexandria Forbes
SELL
62000 shares
2026-03-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
